Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
暂无分享,去创建一个
A. Zhu | M. Borad | G. Abou-Alfa | R. Kelley | A. El-Khoueiry | M. Lowery | J. Bridgewater | J. Valle | D. Catenacci | D. Oh | T. Macarulla | L. Goyal | M. Javle | R. Shroff | S. Lubner | W. Harris | J. Whisenant | S. Pandya | C. Gliser | J. Adeva | J. Cleary | A. Murphy | Liewen Jiang | Camelia Gliser | Bin Fan | Bin Wu | Christina X. Chamberlain